Patents by Inventor Vladimir Kravchenko

Vladimir Kravchenko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Trail enhancers for the selective killing of cancer cells
    Patent number: 9765061
    Abstract: The invention is directed to methods of inducing apoptosis, arresting cell cycle, or inhibiting cellular proliferation, or any combination thereof, in a tumor cell, by administration of an effective amount of an N-acyl homoserine lactone analog (AHL), optionally in conjunction with a tumor modulating agent such tumor necrosis factor (TNF) related apoptosis inducing ligand (TRAIL) to the patient. Novel bioactive analogs of an N-acyl homoserine lactone are also provided.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: September 19, 2017
    Assignee: The Scripps Research Institute
    Inventors: Vladimir Kravchenko, Richard J. Ulevitch, Kim D. Janda
  • TRAIL ENHANCERS FOR THE SELECTIVE KILLING OF CANCER CELLS
    Publication number: 20170101400
    Abstract: The invention is directed to methods of inducing apoptosis, arresting cell cycle, or inhibiting cellular proliferation, or any combination thereof, in a tumor cell, by administration of an effective amount of an N-acyl homoserine lactone analog (AHL), optionally in conjunction with a tumor modulating agent such tumor necrosis factor (TNF) related apoptosis inducing ligand (TRAIL) to the patient. Novel bioactive analogs of an N-acyl homoserine lactone are also provided.
    Type: Application
    Filed: December 22, 2016
    Publication date: April 13, 2017
    Inventors: Vladimir Kravchenko, Richard J. Ulevitch, Kim D. Janda
  • Trail enhancers for the selective killing of cancer cells
    Patent number: 9604950
    Abstract: The invention is directed to methods of inducing apoptosis, arresting cell cycle, or inhibiting cellular proliferation, or any combination thereof, in a tumor cell, by administration of an effective amount of an N-acyl homoserine lactone analog (AHL), optionally in conjunction with a tumor modulating agent such tumor necrosis factor (TNF) related apoptosis inducing ligand (TRAIL) to the patient. Novel bioactive analogs of an N-acyl homoserine lactone are also provided.
    Type: Grant
    Filed: March 19, 2014
    Date of Patent: March 28, 2017
    Assignee: The Scripps Research Institute
    Inventors: Vladimir Kravchenko, Richard J. Ulevitch, Kim D. Janda
  • TRAIL ENHANCERS FOR THE SELECTIVE KILLING OF CANCER CELLS
    Publication number: 20160272603
    Abstract: The invention is directed to methods of inducing apoptosis, arresting cell cycle, or inhibiting cellular proliferation, or any combination thereof, in a tumor cell, by administration of an effective amount of an N-acyl homoserine lactone analog (AHL), optionally in conjunction with a tumor modulating agent such tumor necrosis factor (TNF) related apoptosis inducing ligand (TRAIL) to the patient. Novel bioactive analogs of an N-acyl homoserine lactone are also provided.
    Type: Application
    Filed: March 19, 2014
    Publication date: September 22, 2016
    Inventors: Vladimir Kravchenko, Richard J. Ulevitch, Kim D. Janda